Immune system activation by MF59-adjuvanted H5N1 antigen

The term Immune system – broad cellular and humoral activation by MF59-adjuvanted H5N1 antigen refers to the comprehensive physiological immune response elicited by an influenza vaccine containing the MF59 adjuvant and H5N1 viral antigens. This is not a single molecular target but rather a systemic pharmacological effect involving the coordinated activation of various immune cell subsets. MF59, a squalene-based oil-in-water emulsion, acts by creating a local immunocompetent environment that enhances the recruitment of antigen-presenting cells to the injection site (O'Hagan et al., 2013). These cells capture the H5N1 hemagglutinin antigens and migrate to lymph nodes to stimulate both B-cell-mediated humoral immunity and T-cell-mediated cellular immunity. This broad activation is particularly significant for pandemic influenza preparedness, as H5N1 antigens are often poorly immunogenic in humans when administered without an adjuvant. The use of MF59 allows for dose-sparing and induces a more cross-reactive antibody profile, providing better protection against drifted viral strains (Schultze et al., 2008). Clinical monitoring of this response typically involves measuring neutralizing antibody titers and T-cell cytokine profiles to ensure protective efficacy. While effective, the broad activation of the immune system can lead to common transient side effects such as local inflammation and systemic flu-like symptoms (Gallorini et al., 2015).

Other names

MF59-adjuvanted H5N1 vaccine responseH5N1 vaccine-induced immunityBroad cellular and humoral activation by MF59

MF59 creates a transient immunostimulatory environment at the injection site, inducing the secretion of chemokines (such as CCL2, CCL3, and CXCL8) that recruit monocytes, macrophages, and dendritic cells. These recruited cells take up the H5N1 antigen and transport it to draining lymph nodes, where they facilitate the differentiation of B cells into antibody-secreting plasma cells and the activation of CD4+ T-helper cells (O'Hagan et al., 2013; Gallorini et al., 2015).